Table of contents


Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in November 2016 at the end of the period of market exclusivity.

On 23 December 2005, orphan designation (EU/3/05/339) was granted by the European Commission to Bristol-Myers Squibb Pharma EEIG, United Kingdom, for dasatinib for the treatment of chronic myeloid leukaemia.

Dasatinib has been authorised in the EU as Sprycel since 20 November 2006.

Key facts

Active substance
Medicine name
Disease / condition
Treatment of chronic myeloid leukaemia
Date of first decision
EU designation number

Sponsor's contact details

Bristol-Myers Squibb Pharma EEIG
Uxbridge Business Park
Sanderson Road
Uxbridge UB8 1DH
United Kingdom
Tel. +44 (0)1895 523740
Fax +44 (0)1895 523677

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating